Indivior is a specialty pharmaceuticals business. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. The company was established as the Buprenorphine division of Reckitt Benckiser in 1994. In December 2014, Reckitt Benckiser spun off its specialty pharmaceuticals business into a separate company named Indivior. By February 2015 the company was capitalised at £2.3 billion on the London Stock Exchange. The companys main product is Suboxone, an addiction-control product. Other products include remedies for opioid addiction, cocaine and opioid analgesic overdose and treatment for alcohol dependence: the company claims this to be the largest pipeline of addiction drugs in the world.
Highest paying job titles at Indivior include Account Director, Healthcare Account Director, and Managed Care Director